0001209191-17-034631.txt : 20170523
0001209191-17-034631.hdr.sgml : 20170523
20170523163403
ACCESSION NUMBER: 0001209191-17-034631
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170518
FILED AS OF DATE: 20170523
DATE AS OF CHANGE: 20170523
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lippoldt Darin
CENTRAL INDEX KEY: 0001504783
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 17864168
MAIL ADDRESS:
STREET 1: C/O VOLCANO CORPORATION
STREET 2: 3661 VALLEY CENTRE DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-05-18
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001504783
Lippoldt Darin
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Legal Officer
Common Stock
2017-05-18
4
M
0
10000
18.15
A
23157
D
Common Stock
2017-05-18
4
S
0
10000
53.27
D
13157
D
Non-Qualified Stock Option
18.15
2017-05-18
4
M
0
10000
18.15
D
2015-11-03
2024-11-03
Common Stock
10000
61239
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $52.53 to $53.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option which vests 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018.
/s/Darin Lippoldt
2017-05-22